70-Gene signature in early-stage breast cancer

New England Journal of Medicine

Volumn 375, Issue 22, 2016, Pages 2199-2200

  Thewes, Belinda ^a   Prins, Judith ^a   Friedlander, Michael ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; DNA MICROARRAY; EARLY CANCER; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LETTER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; BREAST TUMOR; GENE EXPRESSION PROFILING; PROGNOSIS;

BREAST NEOPLASMS; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 85002050104     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1612048     Document Type: Letter

References (3)

1. Duric V, Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol 2001;2:691-7.
2. Duric VM, Stockler MR, Heritier S, et al. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now? Ann Oncol 2005;16:1786-94.
3. Ghislain I, Zikos E, Coens C, et al. Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. Lancet Oncol 2016;17(7):e294-e304.